MI |
miR-23a-3p |
Inhibit DMT1 expression |
Inhibit ferroptosis and reduce myocardial injury |
[47] |
BACH1 |
Adjust the threshold of iron ion induction |
Inhibit ferroptosis |
[48] |
Reperfusion injury |
C3G |
Decreased Fe2+, downregulated TfR1 expression, upregulated Fth1 and GPX4 expression |
Inhibit ferroptosis and reduce myocardial injury |
[57] |
Res |
Decreased Fe2+, downregulated TfR1 expression, upregulated Fth1 and GPX4 expression |
Inhibit ferroptosis and reduce myocardial injury |
[58] |
Lip-1 |
Reduce VDAC1 level and increase GPX4 level |
Reduce I/R injury |
[126] |
Eto |
Induced Nrf2 nuclear translocation |
Inhibit I/R-induced ferroptosis, improve fibrosis |
[127] |
AS |
SIRT1 |
Reduce IL-1β and IL-18 levels |
Inhibit ferroptosis and limit AS development |
[64] |
PDSS2 |
Activate Nrf2, inhibit ROS release and reduce iron levels |
Promote the proliferation of HCAECs and limit AS development |
[65] |
miR-17-92 |
Targeting zinc lipoprotein A20 reduces Acsl4 expression and ROS accumulation |
Inhibit ferroptosis |
[66] |
CD98hc |
Unknown |
Promote VSMCs proliferation and prevent atherosclerotic thrombosis |
[34] |
Hypertension |
Monocrotaline (MCT) |
Activate the the HMGB1/TLR4/NLRP3 inflammatory pathway |
Promote ferroptosis |
[73] |
Celastrol |
Increase HO-1 expression and decrease ROS production |
Reduce inflammation and oxidative stress in VSMCs caused by hypertension |
[74] |
CA |
Regulate iron metabolism |
Improve PAH |
[76] |
Elabela |
Regulate the IL-6/STAT3/GPX4 signalling pathway |
Inhibit AngII-induced ferroptosis in poor myocardial remodelling, fibrosis and cardiac dysfunction |
[79] |
Myocardial hypertrophy |
DHA |
Increase IRF3-SLC7A11, decrease ALOX12 and iron levels |
Inhibit ferroptosis |
[128] |
miR-351 |
Regulate the JNK/p53 signalling pathway |
Inhibit ferroptosis and improve fibrosis |
[84] |
LncRNA AAB |
Sponge miR-30b-5p, induced imbalance of MMP9/TIMP1 and enhanced TfR-1 |
Promote ferroptosis |
[86] |
HF |
CD147 |
Activate TRAF2-TAK1 signalling pathway |
Promote cardiac remodelling and dysfunction |
[91] |
TLR4 and NOX4 |
Unknown |
Inhibit cardiac autophagy and ferroptosis in HF rats |
[129] |
DCM |
TRIM46 |
Promote GPX4 ubiquitination |
Resist cell damage caused by high glucose |
[37] |
PA |
Reduce HSF1 and GPX4 |
Promote ferroptosis and enhance endoplasmic reticulum stress |
[39] |
DIC |
EMPA |
Participate in NLRP3- and MYD88-related pathways |
Inhibit ferroptosis, fibrosis, apoptosis and inflammation |
[99] |
AsIV |
Activate Nrf2 signalling pathway and increase GPX4 expression |
Inhibit ferroptosis and improve fibrosis |
[100] |
Sepsis |
LPS |
Activate NCOA4 and SFXN1, increase free iron |
Cause mitochondrial damage and promote ferroptosis |
[108] |
Dexmedetomidine |
Reduce HO-1 expression, increase GPX4 expression |
Reduce sepsis-induced myocardial cell damage |
[107] |
Stroke |
NCOA4 |
USP14 upregulates NCOA4 through deubiquitination |
Silencing NCOA4 can eliminate the ferritinophagy induced by I/R injury |
[102] |
CDKN1A |
C9orf106/C9orf139-miR-22-3p-CDKN1A axes |
Regulate ferroptosis during IS progression |
[104] |
JUN |
GAS5-miR-139-5p/miR-429-JUN axes |
HIF-1α |
Inhibits ACSL4 expression in early IS |
Against ferroptosis |
[105] |